ValiRx plc (GB:VAL) has released an update.
ValiRx PLC has entered into a collaborative agreement with Ignota Labs Limited, aiming to enhance drug development through data sharing, co-development of new assets, and joint business opportunities. The partnership will exploit Inaphaea’s Biobank data and Ignota Labs’ in-silico models to improve oncology asset sourcing and potentially revive clinical candidates previously hindered by toxicity issues. This strategic move is expected to benefit ValiRx’s early-stage evaluation processes and introduce innovative AI methodologies to drug discovery.
For further insights into GB:VAL stock, check out TipRanks’ Stock Analysis page.
